A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 3, 2014, Pages 252-258

  Joshua, A M ^a   Zannella, V E ^a   Downes, M R ^a,b   Bowes, B ^a   Hersey, K ^a   Koritzinsky, M ^a   Schwab, M ^c,d   Hofmann, U ^c,d   Evans, A ^a,b   Van Der Kwast, T ^a,b   Trachtenberg, J ^a,c,d   Finelli, A ^a,c,d   Fleshner, N ^a,b   Sweet, J ^a,b   Pollak, M ^e  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; KI 67 ANTIGEN; METFORMIN; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT DURATION; ADJUVANT THERAPY; BIOPSY; BLOOD; CANCER GRADING; CANCER STAGING; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY; HUMANS; MALE; METFORMIN; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PILOT PROJECTS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906322620     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2014.20     Document Type: Article

References (30)

1. Society AC. Global Cancer Facts & Figures, 2nd edn. (Society AC), 2011.
2. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-3586.
3. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG. Insulinlowering effects of metformin in women with early breast cancer. Clin Breast Cancer 2008; 8: 501-505.
4. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate 2002; 50: 1-3.
5. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Br J Cancer 2002; 87: 726-728.
6. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL et al. Prediagnostic bodymass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9: 1039-1047.
7. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E et al. Insulin receptor expression by human prostate cancers. Prostate 2009; 69: 33-40.
8. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013; 8: e71583.
9. Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie K. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 349-357.
10. Margel D, Urbach D, Lipscombe LL, Bell CM, Kulkarni G, Austin PC et al. Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst 2013; 105: 1123-1131.
11. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013 Apr; 63: 709-716.
12. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013; 31: 3069-3075.
13. Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012; 135: 821-830.
14. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncology 2009; 27: 3297-3302.
15. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011; 128: 783-794.
16. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012; 30: 2593-2600.
17. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 2011; 71: 4366-4372.
18. Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A et al. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis 2012; 15: 346-352.
19. Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD, Pearson RB. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors 2007; 25: 209-226.
20. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004; 167: 399-403.
21. Stambolic V, Woodgett JR, Fantus IG, Pritchard KI, Goodwin PJ. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Breast Cancer Res Treatment 2009; 114: 387-389.
22. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. J Biochem 2000; 348(Pt 3): 607-614.
23. Obinata D, Takayama K, Urano T, Murata T, Kumagai J, Fujimura T et al. Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer. Int J Cancer 2012; 130: 1021-1028.
24. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M et al. Towards a knowledge-based human protein atlas. Nat Biotechnol 2010; 28: 1248-1250.
25. Verhoven B, Yan Y, Ritter M, Khor LY, Hammond E, Jones C et al. Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08. Int J Radiat Oncol Biol Phys 2013; 86: 317-323.
26. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996; 178: 437-441.
27. Zellweger T, Gunther S, Zlobec I, Savic S, Sauter G, Moch H et al. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or lowgrade prostate cancer. Int J Cancer 2009; 124: 2116-2123.
28. Bubendorf L, Tapia C, Gasser TC, Casella R, Grunder B, Moch H et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998; 29: 949-954.
29. Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst 2013; 105: 1881-1890.
30. Rothermundt CA, Cathomas R, Templeton A, Winterhalder RC, Strebel R, Baertschi D, Pollak M, Lui L, Crowe S, Gillessen S (eds). Metformin in Chemotherapy-Ná̈ve Castration Resistant Prostate Cancer (CRPC): A Multicenter Phase II Trial (SAKK 08/09). ESMO: Vienna, 2012.